Bio­gen pulls the plug on prized IPF drug from $562M+ Stromedix buy­out

One of Bio­gen’s at­tempts to branch out has flopped as the biotech scraps a mid-stage pro­gram for id­io­path­ic pul­monary fi­bro­sis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.